JP2020519675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020519675A5 JP2020519675A5 JP2019563246A JP2019563246A JP2020519675A5 JP 2020519675 A5 JP2020519675 A5 JP 2020519675A5 JP 2019563246 A JP2019563246 A JP 2019563246A JP 2019563246 A JP2019563246 A JP 2019563246A JP 2020519675 A5 JP2020519675 A5 JP 2020519675A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- immunoconjugate
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023096307A JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506940P | 2017-05-16 | 2017-05-16 | |
| US62/506,940 | 2017-05-16 | ||
| US201762560462P | 2017-09-19 | 2017-09-19 | |
| US62/560,462 | 2017-09-19 | ||
| US201862647008P | 2018-03-23 | 2018-03-23 | |
| US62/647,008 | 2018-03-23 | ||
| PCT/US2018/032692 WO2018213260A1 (en) | 2017-05-16 | 2018-05-15 | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096307A Division JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020519675A JP2020519675A (ja) | 2020-07-02 |
| JP2020519675A5 true JP2020519675A5 (enExample) | 2022-05-18 |
Family
ID=64269828
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563246A Pending JP2020519675A (ja) | 2017-05-16 | 2018-05-15 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ−１抗体の組み合わせ |
| JP2023096307A Pending JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096307A Pending JP2023113921A (ja) | 2017-05-16 | 2023-06-12 | 抗ｆｏｌｒ１イムノコンジュゲートと抗ｐｄ－１抗体の組み合わせ |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20180333503A1 (enExample) |
| EP (1) | EP3625262A4 (enExample) |
| JP (2) | JP2020519675A (enExample) |
| KR (1) | KR20200006546A (enExample) |
| CN (2) | CN118078987A (enExample) |
| AU (1) | AU2018269173A1 (enExample) |
| BR (1) | BR112019023909A8 (enExample) |
| CA (1) | CA3063893A1 (enExample) |
| IL (1) | IL314823A (enExample) |
| MX (1) | MX2019013753A (enExample) |
| RU (1) | RU2019141270A (enExample) |
| TW (3) | TW202322853A (enExample) |
| WO (1) | WO2018213260A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| ES2661466T3 (es) | 2011-04-01 | 2018-04-02 | Immunogen, Inc. | Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1 |
| EP3765521A4 (en) | 2018-03-13 | 2022-03-23 | Phanes Therapeutics, Inc. | ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF |
| JP2022500454A (ja) * | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | 抗葉酸受容体抗体コンジュゲートによる併用療法 |
| MX2021008121A (es) * | 2019-01-03 | 2021-12-10 | Inst Nat Sante Rech Med | Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer. |
| AU2022263376A1 (en) | 2021-04-23 | 2023-11-23 | King's College London | Composition comprising an ige antibody |
| TW202409080A (zh) * | 2022-07-26 | 2024-03-01 | 美商沙塔克實驗室股份有限公司 | 用於治療卵巢癌之組合療法 |
| CN115960269B (zh) * | 2023-01-30 | 2026-04-03 | 上海甲贝医药科技有限公司 | 一种重组长效人cxcr4&pd-1双靶点抗体融合蛋白及其制备方法 |
| CN120919340A (zh) * | 2024-05-09 | 2025-11-11 | 百奥泰生物制药股份有限公司 | 抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用 |
| CN118684782A (zh) * | 2024-07-17 | 2024-09-24 | 武汉科技大学 | 一种muc16和folr1双靶点嵌合抗原受体dcar-16-r1及应用 |
| WO2026056954A1 (en) * | 2024-09-12 | 2026-03-19 | LaNova Medicines Limited | Anti-folr1 antibodies and conjugates thereof |
| CN119798405B (zh) * | 2024-12-30 | 2026-06-30 | 华润生物医药有限公司 | Il-21的突变体及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2170959E (pt) * | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| CN105777907B (zh) * | 2010-02-24 | 2020-03-17 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| BR112015007184A2 (pt) * | 2012-10-02 | 2017-08-08 | Bristol Myers Squibb Co | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer |
| JP6463744B2 (ja) * | 2013-10-08 | 2019-02-06 | イミュノジェン， インコーポレイテッド | 抗ｆｏｌｒ１免疫抱合体投薬レジメン |
| US20150297744A1 (en) * | 2014-03-28 | 2015-10-22 | Immunogen, Inc. | Anti-FOLR1 Immunoconjugate Dosing Regimens |
| SG11201704056XA (en) * | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| EP3233918A1 (en) * | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| CN122075735A (zh) * | 2015-09-17 | 2026-05-26 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
-
2018
- 2018-05-15 BR BR112019023909A patent/BR112019023909A8/pt not_active IP Right Cessation
- 2018-05-15 CA CA3063893A patent/CA3063893A1/en active Pending
- 2018-05-15 IL IL314823A patent/IL314823A/en unknown
- 2018-05-15 EP EP18802195.0A patent/EP3625262A4/en not_active Withdrawn
- 2018-05-15 WO PCT/US2018/032692 patent/WO2018213260A1/en not_active Ceased
- 2018-05-15 CN CN202410214686.8A patent/CN118078987A/zh active Pending
- 2018-05-15 RU RU2019141270A patent/RU2019141270A/ru unknown
- 2018-05-15 JP JP2019563246A patent/JP2020519675A/ja active Pending
- 2018-05-15 MX MX2019013753A patent/MX2019013753A/es unknown
- 2018-05-15 US US15/979,989 patent/US20180333503A1/en not_active Abandoned
- 2018-05-15 AU AU2018269173A patent/AU2018269173A1/en not_active Abandoned
- 2018-05-15 KR KR1020197034686A patent/KR20200006546A/ko not_active Ceased
- 2018-05-15 CN CN201880032356.XA patent/CN110799535A/zh active Pending
- 2018-05-16 TW TW111134010A patent/TW202322853A/zh unknown
- 2018-05-16 TW TW107116641A patent/TW201900221A/zh unknown
- 2018-05-16 TW TW113100663A patent/TW202440170A/zh unknown
-
2021
- 2021-07-21 US US17/382,286 patent/US20220160889A1/en not_active Abandoned
-
2023
- 2023-06-12 JP JP2023096307A patent/JP2023113921A/ja active Pending
- 2023-10-18 US US18/489,292 patent/US20240299571A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6800853B2 (ja) | 抗ｃ１０ｏｒｆ５４抗体およびその使用 | |
| CN113924318B (zh) | 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法 | |
| JP2025129187A5 (enExample) | ||
| TWI912619B (zh) | 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌 | |
| US12246025B2 (en) | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate | |
| RU2019141270A (ru) | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител | |
| CN115485304B (zh) | 抗体药物偶联物及其制剂 | |
| US12324841B2 (en) | Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| US20210030888A1 (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| CN110475569A (zh) | 通过施用抗her3抗体-药物偶联物实现的egfr-tki耐受性的非小细胞肺癌的治疗方法 | |
| CA3118542A1 (en) | Cdcp1-targeted therapies | |
| CA3080137A1 (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| WO2018072743A1 (zh) | Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途 | |
| EP4561623A1 (en) | Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| WO2026092660A1 (zh) | 抗her2抗体药物偶联物和抗pd-l1抗体联合在制备治疗乳腺癌的药物中的用途 | |
| TW202615102A (zh) | 抗體藥物偶聯物用於治療癌症的方法 | |
| HK40084048B (en) | Antibody-drug conjugate and preparation thereof | |
| WO2025190318A1 (zh) | 抗her2抗体药物偶联物和her二聚化抑制剂联合治疗实体瘤 | |
| WO2025256641A1 (zh) | 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤 | |
| CN115611981A (zh) | 抗pd-1抗体在治疗外周t细胞淋巴瘤中的应用 | |
| CN115607663A (zh) | 抗pd-1抗体在治疗原发纵隔大b细胞淋巴瘤中的应用 | |
| CN119607196A (zh) | 抗lag-3抗体与抗pd-1抗体的应用 | |
| CN116490209A (zh) | 联合疗法及其使用方法 |